MDT Medtronic plc.

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Recent Analyst Ratings for Medtronic plc.

Date	Price Target	Rating	Analyst
6/16/2025	$110.00	Outperform	Leerink Partners
3/4/2025	$92.00 → $107.00	Neutral → Buy	Citigroup
10/10/2024	$98.00 → $105.00	Sector Perform → Outperform	RBC Capital Mkts
8/21/2024	$92.00 → $94.00	Perform	Oppenheimer
8/15/2024	$76.00 → $90.00	Sell → Neutral	UBS
8/14/2024	$100.00 → $85.00	Buy → Hold	Stifel
5/30/2024	$83.00	Sell	Goldman
7/19/2023	$90.00	Neutral	Robert W. Baird
6/30/2023	$106.00	Buy	CL King
5/30/2023	$104.00	Equal-Weight → Overweight	Morgan Stanley

See more ratings

Medtronic plc.

Peers

Recent Analyst Ratings for Medtronic plc.

Medtronic plc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Accounting Officer Blomquist Denise L. gifted 310 units of Ordinary Shares, decreasing direct ownership by 3% to 10,143 units (SEC Form 4)

New insider Kiil Harry Skip claimed ownership of 33,442 units of Ordinary Shares (SEC Form 3)

SVP, Chief HR Officer Walter Matthew R. covered exercise/tax liability with 34 units of Ordinary Shares, decreasing direct ownership by 0.13% to 26,054 units (SEC Form 4)

Chief Accounting Officer Blomquist Denise L. was granted 2,975 units of Ordinary Shares, increasing direct ownership by 40% to 10,453 units (SEC Form 4)

Director Powell Kendall J was granted 2,083 units of Ordinary Shares and covered exercise/tax liability with 216 units of Ordinary Shares, increasing direct ownership by 4% to 48,622 units (SEC Form 4)

Director Nabel Elizabeth G was granted 2,083 units of Ordinary Shares and covered exercise/tax liability with 216 units of Ordinary Shares, increasing direct ownership by 12% to 17,615 units (SEC Form 4)

Director Lofton Kevin E was granted 2,083 units of Ordinary Shares and covered exercise/tax liability with 216 units of Ordinary Shares, increasing direct ownership by 30% to 8,171 units (SEC Form 4)

Director Lewis Gregory P was granted 2,083 units of Ordinary Shares and covered exercise/tax liability with 181 units of Ordinary Shares, increasing direct ownership by 101% to 3,785 units (SEC Form 4)

Director Hogan Randall J was granted 2,083 units of Ordinary Shares and covered exercise/tax liability with 216 units of Ordinary Shares, increasing direct ownership by 4% to 47,029 units (SEC Form 4)

Director Goldsmith Andrea Jo was granted 2,083 units of Ordinary Shares and covered exercise/tax liability with 216 units of Ordinary Shares, increasing direct ownership by 22% to 10,247 units (SEC Form 4)

Medtronic plc. SEC Filings

SEC Form SD filed by Medtronic plc.

Medtronic plc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Other Events, Financial Statements and Exhibits

Medtronic plc. filed SEC Form 8-K: Leadership Update

SEC Form 10-Q filed by Medtronic plc.

Medtronic plc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 144 filed by Medtronic plc.

Medtronic plc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

SEC Form 144 filed by Medtronic plc.

SEC Form 10-Q filed by Medtronic plc.

Medtronic plc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Medtronic plc. Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Leerink Partners initiated coverage on Medtronic with a new price target

Medtronic upgraded by Citigroup with a new price target

Medtronic upgraded by RBC Capital Mkts with a new price target

Oppenheimer reiterated coverage on Medtronic with a new price target

Medtronic upgraded by UBS with a new price target

Medtronic downgraded by Stifel with a new price target

Goldman initiated coverage on Medtronic with a new price target

Robert W. Baird initiated coverage on Medtronic with a new price target

CL King initiated coverage on Medtronic with a new price target

Medtronic upgraded by Morgan Stanley with a new price target

Medtronic plc. Press Releases

Fastest customizable press release news feed in the world

Medtronic announces MiniMed as name for planned New Diabetes Company

AI in Healthcare Just Crossed a Tipping Point. Investors Are Watching These Names

Medtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference

Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

Medtronic announces intent to separate Diabetes business

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

Medtronic to announce financial results for its fourth quarter and full fiscal year 2025

New survey: 1 in 3 women have not talked to their doctor about heart health, the #1 killer of women

Medtronic Affera™ pulsed field ablation technologies continue to demonstrate promising evidence for atrial fibrillation patients

Medtronic Expand URO U.S. clinical trial meets safety and effectiveness primary endpoints for Hugo™ robotic-assisted surgery system